HR+ BC appears to evolve by evading NK cell-dependent immunosurveillance, suggesting that NK cell-activating strategies, including nutritional measures like NAM, as well as specific antibodies targeting NK cell receptors, may improve the efficacy of (immuno)therapeutic agents currently employed in the clinics for HR+ BC patients. Here, KLRD1 is linked to breast cancer.